How optimizing RBQM risk detection reduces the efforts caused by false signals.
Jonathan Rowe, PhD, MS, MA
Advertisement
Jonathan Rowe, PhD, MS, MA, has worked in the pharmaceutical industry across clinical, quality and corporate teams for over 25 years. He currently leads ZS’s clinical development quality, operations and risk management functions from the New York office.
Articles by Jonathan Rowe, PhD, MS, MA
Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Optimizing feasibility through increased data collection.
A case study by Pfizer & The Avoca Group on the development of an overarching strategy for Pfizer’s clinical trial quality metrics.
Advertisement
Latest Updated Articles
The Eradication of False Signals in MonitoringPublished: September 7th 2022 | Updated:
Quality Metrics for Clinical TrialsPublished: July 8th 2015 | Updated:
- Towards Data-Driven Clinical Trial Planning and Strategy
Published: December 16th 2021 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Global Breast Cancer Trials Show Progress in Diversity, But Gaps Remain
2
Bringing Clinical Trials Into the Digital Era with eConsent
3
ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition
4
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
